摘要
Objective To investigate the safety and efficacy of treating patients with acute non-ST-segment elevation myocardial infarction(NSTEMI)and elevated levels of N-terminal pro-hormone B-type natriuretic peptide(NTproBNP)with levosimendan within 24 hours of first medical contact(FMC).
作者
徐峰
XU Feng(Dept Emerg Med,Qilu Hosp,Shandong Univ,Acute Heart Failure Unit(AHFU),Shandong Prov Clin Res Center,Emerg&Critical Care Med,Instit Emerg&Critical Care Med,Shandong Univ,Key Lab Emerg&Critical Care Med,Key Lab,Cardiopulmonary-Cerebral Resuscit Res,Shandong Prov Engineering Lab,Emerg&Critical Care Med,Jinan 250012)
